We showed previously that the mouse cross-reactive KD033-surrogate had increased safety compared to the non-targeting IL-15 and significant anti-tumor activity in mouse tumor models that are non- or minimally responsive to IL-15 or anti-PD-L1 monotherapy [8]. The gene discussed is CD274; the disease is neoplasm.